Proactive Investors - Run By Investors For Investors

Physiomics spies possible ‘nearer-term’ revenues from latest cancer tool

As part of an Innovate UK-funded project, Physiomics has developed a tool that could potentially help doctors work out how much of a chemotherapy drug should be prescribed to individual patients
iv drip in hospital
Physiomics received £68,000 from Innovate UK to cover the costs of the research

Physiomics Plc (LON:PYC) believes revenues from a tool it has developed as part of a project funded by Innovate UK could potentially be just around the corner.

Generally, doctors prescribe cancer patients with the same amount of a chemotherapy drug, but this can lead to under- or over-dosing individual patients, as each will respond differently.

As part of an Innovate UK-funded project, Physiomics has developed a tool that, from a simple blood test, could provide clinicians with a prediction of both toxicity and efficacy for any given dose.

READ: Renewal of key Merck contract caps off strong first half for Physiomics

They could then use this information to tailor the treatment to individual patients. This could potentially reduce the costs and morbidity associated with over-dosing, while it could also improve efficacy as a result of under-dosing.

Physiomics has said today it is exploring the approval of the tool as a medical device, although this would likely require further clinical validation before it could be commercialised.

But bosses pointed out that the tool could be used earlier in research settings, “thus creating the possibility of nearer term revenue potential”.

In support of the tool’s possible commercialisation, the AIM company is approaching potential strategic partners, clinical collaborators and grant providers to help it progress this “exciting opportunity”.

It has already presented a poster on the project at this year’s American Association for Cancer Research, which helped to drum up interest, while it has also spoken with the Oxford Academic Health Sciences Network and the National Institute for Health Research signposting service.

Physiomics cautioned that there is no guarantee this project will progress, although they will make an announcement later in the year should anything come of its discussions.

View full PYC profile View Profile

Physiomics Plc Timeline

Related Articles

man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use